Condition
PSMA PET
Total Trials
6
Recruiting
4
Active
6
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (2)
Trial Status
Recruiting4
Active Not Recruiting2
Clinical Trials (6)
Showing 6 of 6 trials
NCT07052214Phase 3Recruiting
PSMA PET Combined With MRI for the Detection of PCa
NCT07608419Active Not Recruiting
Predictors of Nodal and Distant Metastatic Disease Detected by PSMA PET in Treatment-Naïve High-Risk Prostate Cancer: A Czech Multicentre Cohort Study
NCT07553754Recruiting
Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis
NCT07553780Recruiting
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
NCT04987086Not ApplicableRecruiting
68Ga-PSMA PET in the Renal Cell Carcinoma
NCT05622162Phase 3Active Not Recruiting
Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
Showing all 6 trials